Ironwood Pharmaceuticals | IRWD - Operating Expenses


Ironwood Pharmaceuticals reported $57.33M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 270.12M 2.55M Jun/2026
Agios Pharmaceuticals USD 130.77M 10.77M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
Almirall EUR 531.16M 13.76M Jun/2026
Alnylam Pharmaceuticals USD 1.06B 160.97M Jun/2026
Amarin USD 51.48M 113K Dec/2025
Ardelyx USD 127.27M 7.15M Mar/2026
Astellas Pharma JPY 455.56B 33.8B Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Charles River Laboratories USD 2.84B 1.96B Jun/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Halozyme Therapeutics USD 192.19M 18.88M Mar/2026
Incyte USD 973.64M 4.65B Jun/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Lexicon Pharmaceuticals USD 20.27M 6.1M Dec/2025
MacroGenics USD 21.2M 32.13M Mar/2026
Moderna USD 960M 817M Jun/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Pacira USD 180.54M 7.79M Jun/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Takeda JPY 1.02T 89.68B Jun/2026
Ultragenyx Pharmaceutical USD 289M 16M Jun/2026
Vanda Pharmaceuticals USD -1.14B 1.6B Dec/2025